OncLive: Phase 3 MOMENTUM Study Completes Enrollment in Myelofibrosis
July 5, 2021
Dr. Ruben Mesa, executive director of the Mays Cancer Center, is quoted in this story about a clinical trial. Read more
San Antonio Business Journal: SA cancer center to expand research diversity with national clinical trial
July 1, 2021
Dr. Ruben Mesa, executive director of the Mays Cancer Center, was quoted in this story about the Mays Cancer Center at UT Health San Antonio joining three other institutions to participate in a new Advancing Inclusive Research Site Alliance launched by San Francisco-based Genentech. Read story
Nearly all patients with cancer respond well to COVID-19 vaccines
July 1, 2021
In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.
Mays Cancer Center selected as founding partner of oncology clinical trial diversity alliance
June 23, 2021
The Mays Cancer Center, home to UT Health San Antonio MD Anderson, was named a founding partner of the Advancing Inclusive Research® Site Alliance.
Targeted Oncology: Transfusion independence at 24 weeks linked to improved OS on momelotinib in myelofibrosis
June 11, 2021
Dr. Ruben Mesa, executive director of the Mays Cancer Center, is quoted in this Targeted Oncology story. Read the story.
Spectrum News: $9.8M study will follow 3,000 Latino cancer survivors
June 11, 2021
Dr. Amelie Ramirez, Institute for Health Promotion Research, Salud America!, Population Health Sciences, Mays Cancer Center, was interviewed by Spectrum News about a $9.8 million study focused on the Latino cancer survivorship experience. Watch the story.